Bank of Nova Scotia
TBPH

Bank of Nova Scotia’s Theravance Biopharma TBPH Stock Holding History

Bank of Nova Scotia’s Portfolio TBPH Stock Details TBPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-10,649
Closed -$199K – 1204
2025
Q4 		$199K Buy
+10,649
New +$177K ﹤0.01% 1041
2022
Q2 		– Sell
-21,652
Closed -$207K – 1264
2022
Q1 		$207K Sell
21,652
-3,831
-15% -$37.5K ﹤0.01% 1148
2021
Q4 		$282K Buy
+25,483
New +$222K ﹤0.01% 1155

Other funds holding TBPH

MAP
Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $9.54B AUM 55.06% 1-Year Est. Return
NM
Newtyn Management New York $801M AUM 23.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ICM
Irenic Capital Management New York $2.08B AUM 19.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Bank of Nova Scotia's TBPH Position: Q1 2026 in Review

Bank of Nova Scotia sold out of Theravance Biopharma (TBPH) in Q1 2026, closing a stake of 10,649 shares — an estimated $199K sold.

Bank of Nova Scotia first reported a position in TBPH in Q4 2021 and held it in 3 quarters. The position peaked at $282K in Q4 2021. 174 funds tracked by Wall St. Rank hold TBPH as of Q1 2026.

  • Bank of Nova Scotia reported no remaining Theravance Biopharma position as of Q1 2026 after selling out during the quarter.
  • Bank of Nova Scotia sold 10,649 Theravance Biopharma shares in Q1 2026, an estimated $199K.
  • Bank of Nova Scotia first reported a position in Theravance Biopharma in Q4 2021 and held it in 3 quarters.
  • Bank of Nova Scotia's Theravance Biopharma position peaked at $282K in Q4 2021.
  • 174 funds tracked by Wall St. Rank held Theravance Biopharma as of Q1 2026.

Based on Bank of Nova Scotia's 13F filing for Q1 2026, filed 14 May 2026.